59.9K
views
52
authors
10
articles
Editors
3
Impact
Loading...
Review
17 April 2020
Intracellular Trafficking Mechanisms of Synaptic Dysfunction in Alzheimer’s Disease
Catarina Perdigão
4 more and 
Cláudia Guimas Almeida
Gene ontology (GO) analysis of LOAD risk factors reveals the enrichment of genes in the trafficking pathway. Nearly half of the 37 LOAD putative risk factors identified by genome-wide association studies (GWAS) meta-analysis (Lambert et al., 2013; Jansen et al., 2019; Kunkle et al., 2019), have been functionally grouped by GO analysis in three main pathways: trafficking (orange), immune response (blue), and lipid metabolism (green). GO analysis was performed using the Cytoscape StringApp (Doncheva et al., 2019).

Alzheimer’s disease (AD) is the most common neurodegenerative disease characterized by progressive memory loss. Although AD neuropathological hallmarks are extracellular amyloid plaques and intracellular tau tangles, the best correlate of disease progression is synapse loss. What causes synapse loss has been the focus of several researchers in the AD field. Synapses become dysfunctional before plaques and tangles form. Studies based on early-onset familial AD (eFAD) models have supported that synaptic transmission is depressed by β-amyloid (Aβ) triggered mechanisms. Since eFAD is rare, affecting only 1% of patients, research has shifted to the study of the most common late-onset AD (LOAD). Intracellular trafficking has emerged as one of the pathways of LOAD genes. Few studies have assessed the impact of trafficking LOAD genes on synapse dysfunction. Since endocytic traffic is essential for synaptic function, we reviewed Aβ-dependent and independent mechanisms of the earliest synaptic dysfunction in AD. We have focused on the role of intraneuronal and secreted Aβ oligomers, highlighting the dysfunction of endocytic trafficking as an Aβ-dependent mechanism of synapse dysfunction in AD. Here, we reviewed the LOAD trafficking genes APOE4, ABCA7, BIN1, CD2AP, PICALM, EPH1A, and SORL1, for which there is a synaptic link. We conclude that in eFAD and LOAD, the earliest synaptic dysfunctions are characterized by disruptions of the presynaptic vesicle exo- and endocytosis and of postsynaptic glutamate receptor endocytosis. While in eFAD synapse dysfunction seems to be triggered by Aβ, in LOAD, there might be a direct synaptic disruption by LOAD trafficking genes. To identify promising therapeutic targets and biomarkers of the earliest synaptic dysfunction in AD, it will be necessary to join efforts in further dissecting the mechanisms used by Aβ and by LOAD genes to disrupt synapses.

9,393 views
43 citations
13,365 views
52 citations
Review
02 July 2019

Rett syndrome (RTT) is an X-linked neurodevelopmental disorder caused mainly by mutations in the MECP2 gene, being one of the leading causes of mental disability in females. Mutations in the MECP2 gene are responsible for 95% of the diagnosed RTT cases and the mechanisms through which these mutations relate with symptomatology are still elusive. Children with RTT present a period of apparent normal development followed by a rapid regression in speech and behavior and a progressive deterioration of motor abilities. Epilepsy is one of the most common symptoms in RTT, occurring in 60 to 80% of RTT cases, being associated with worsening of other symptoms. At this point, no cure for RTT is available and there is a pressing need for the discovery of new drug candidates to treat its severe symptoms. However, despite being a rare disease, in the last decade research in RTT has grown exponentially. New and exciting evidence has been gathered and the etiopathogenesis of this complex, severe and untreatable disease is slowly being unfolded. Advances in gene editing techniques have prompted cure-oriented research in RTT. Nonetheless, at this point, finding a cure is a distant reality, highlighting the importance of further investigating the basic pathological mechanisms of this disease. In this review, we focus our attention in some of the newest evidence on RTT clinical and preclinical research, evaluating their impact in RTT symptomatology control, and pinpointing possible directions for future research.

9,510 views
14 citations
Open for submission
Frontiers Logo

Frontiers in Neuroscience

Neuroenergetics in Health and Disease
Edited by Ola Awad, Jaylyn Waddell
Deadline
31 July 2024
Submit a paper
Recommended Research Topics
Frontiers Logo

Frontiers in Pharmacology

New Paradigms in Neuroscience and Related Targets for Drug Discovery, Volume I
Edited by Salvatore Salomone
174.9K
views
106
authors
21
articles
Frontiers Logo

Frontiers in Molecular Neuroscience

Fundamentals of 21st Century Neuroscience
Edited by Pierre J Magistretti, Toru Takahata
451.2K
views
149
authors
32
articles
Frontiers Logo

Frontiers in Neuroscience

Listening in Action: Attention, Emotions and Cognition in the Auditory System
Edited by Diego Elgueda, Yaneri A. Ayala, Daniel Duque, Paul Hinckley Delano
17.1K
views
23
authors
5
articles
Frontiers Logo

Frontiers in Pharmacology

New Paradigms in Neuroscience and Related Targets for Drug Discovery, Volume II
Edited by Salvatore Salomone
14.8K
views
38
authors
5
articles
Frontiers Logo

Frontiers in Computational Neuroscience

Computational Modeling and Machine Learning Methods in Neurodevelopment and Neurodegeneration: from Basic Research to Clinical Applications
Edited by Pablo Martinez-Cañada, Noemi Montobbio, Roberto Maffulli, Anees Abrol
33.4K
views
85
authors
11
articles